BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34933335)

  • 1. Impact of preoperative tumor rupture timing on gastrointestinal stromal tumor prognosis: a retrospective multicentric cohort study.
    Chiguchi G; Cho H; Sato S; Takahashi T; Nabeshima K; Maruyama T; Kataoka M; Katayanagi S; Kikuchi H
    Jpn J Clin Oncol; 2022 Mar; 52(3):237-243. PubMed ID: 34933335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study.
    Hølmebakk T; Hompland I; Bjerkehagen B; Stoldt S; Bruland ØS; Hall KS; Boye K
    Ann Surg Oncol; 2018 May; 25(5):1133-1139. PubMed ID: 29435684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Definition of tumor rupture in gastrointestinal stromal tumor].
    Zhou YB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):762-768. PubMed ID: 34530556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
    Lei C; Liu L; Wang Q; Wang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1300-1304. PubMed ID: 27928804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
    Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
    Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
    Hohenberger P; Bonvalot S; van Coevorden F; Rutkowski P; Stoeckle E; Olungu C; Litiere S; Wardelmann E; Gronchi A; Casali P
    Eur J Cancer; 2019 Oct; 120():47-53. PubMed ID: 31479947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.
    Nishida T; Cho H; Hirota S; Masuzawa T; Chiguchi G; Tsujinaka T;
    Ann Surg Oncol; 2018 Jul; 25(7):1961-1969. PubMed ID: 29752602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

  • 12. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
    Han D; Deneve J; Gonzalez RJ
    Am Surg; 2012 Jan; 78(1):74-9. PubMed ID: 22273319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.
    Huang H; Liang H; Zhan ZL; Li H; Ren XB; Hao XS
    Med Oncol; 2012 Jun; 29(2):941-7. PubMed ID: 21390518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
    Lei C; Zhao B; Wang Q; Ge L; Wang H
    J BUON; 2018; 23(2):460-467. PubMed ID: 29745093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
    Hou Q; Luo W; Li L; Dai Y; Jiang L; Wang A; Chu X; Li Y; Yang D; Lu C; Yao L; Cui G; Lin H; Chen G; Cui Q; Zhang H; Lun Z; Xia L; Su Y; Han G; Hui X; Wei Z; Sun Z; Guo H; Zhou Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1025-1030. PubMed ID: 28900994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
    Lu J; Dai Y; Zheng HL; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Li P; Huang CM; Zheng CH
    Medicine (Baltimore); 2019 Jan; 98(3):e14177. PubMed ID: 30653164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
    Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
    Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
    Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
    Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
    Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
    Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
    World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.